We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

BEAMing Technology Effectively Detects Cancer-Linked Mutations in Liquid Biopsy Samples

By LabMedica International staff writers
Posted on 19 Jul 2015
Print article
Image: The principle of blood-based DNA testing (Photo courtesy of Sysmex-Inostics).
Image: The principle of blood-based DNA testing (Photo courtesy of Sysmex-Inostics).
Liquid biopsy using BEAMing technology was found to be an effective method for analyzing tumor genotypes in real time and identifying significant mutations that occur during the course of disease and are not detected by tissue biopsy.

Rapid developments in the technology and protocols required for reliably isolating and analyzing circulating tumor DNA (ctDNA) in peripheral blood are making it easier to obtain the necessary samples without the need for physical biopsies. One such method, developed by Sysmex-Inostics (Kobe, Japan), utilizes digital PCR to detect somatic tumor mutations in ctDNA with high sensitivity. The technique combines emulsion digital PCR and flow cytometry. Known as BEAMing, it employs a combination of beads, emulsification, amplification, and magnetics to achieve the necessary level of sensitivity.

The BEAMing process starts with isolating and purifying the DNA present in blood plasma, which then goes through a pre-amplification step using conventional PCR to amplify the genetic section of interest using primers incorporating known tag sequences. These DNA templates are then amplified again via emulsion PCR, employing primers directed at these sequence tags and covalently bound to magnetic microbeads via streptavidin–biotin interactions. By designing the system this way, the PCR products generated in each emulsion droplet will remain physically affixed to the microbeads at the end of the reaction, allowing them to be easily separated and purified using a magnet. The method also provides a digital readout of copy number, as it has been experimentally optimized to ensure that each emulsion droplet will contain a maximum of one microbead and one DNA template molecule. This makes it possible to detect even very rare mutant templates at copy ratios greater than 1:10,000.

BEAMing technology was used to analyze the DNA in 503 blood samples acquired from patients with metastatic colorectal cancer participating in the CORRECT (previously treated metastatic colorectal cancer) phase III trial.

Results revealed that tumor-associated mutations could readily be detected by BEAMing of plasma DNA, with KRAS mutations identified in 69% of patients, PIK3CA mutations in 17% of patients, and BRAF mutations in 3% of patients. The results also showed that the drug regorafenib seemed to be consistently associated with a clinical benefit in a range of patient subgroups based on mutational status and protein biomarker concentrations.

Regorafenib (commercial name Stivarga) is an oral multi-kinase inhibitor, which targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows antiangiogenic activity due to its dual targeted VEGFR2-TIE2 (vascular endothelial growth factor receptor 2 - tyrosine kinase with immunoglobulin-like and EGF-like domains 2) tyrosine kinase inhibition. Regorafenib has been shown to increase the overall survival of patients with metastatic colorectal cancer and is currently being studied as a potential treatment option in multiple tumor types.

"This is the first large clinical trial to compare liquid versus conventional tissue biopsy data, and the results show the former (BEAMing technology) obtain more data on tumor mutation throughout the course of the disease, enabling us to better target therapy to the specificities of patient's tumor; this could have a considerable impact on clinical practice, as novel applications of this technology could be further investigated and developed," said first author Dr. Josep Tabernero, head of the medical oncology department at the Vall d'Hebron Institute of Oncology (Barcelona, Spain).

The CORRECT BEAMing study was published in the July 13, 2015, online edition of the journal the Lancet Oncology.

Related Links:

Sysmex-Inostics
Vall d'Hebron Institute of Oncology


Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
New
Silver Supplier
Monkeypox Virus Real Time PCR Test
Monkeypox Virus Real Time PCR Detection Kit
New
Albumin Urine Test
Micro-Albumin ELISA
New
Automatic IFA Processor
AP 16 IF ELITE

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.